Checkpoint Therapeutics (CKPT) announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca (AZN) Rare Disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CKPT:
- Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
- CKPT Earnings this Week: How Will it Perform?
- Checkpoint Therapeutics Faces Nasdaq Compliance Challenge
- Biotech Alert: Searches spiking for these stocks today
- Checkpoint Therapeutics Announces Recent Offering Pricing